journal article·2021-06

Crystal structure of tamsulosin hydrochloride, C 20 H 29 N 2 O 5 SCl

Nilan V. Patel, Joseph T. Golab, James A. Kaduk, Amy M. Gindhart, Thomas N. Blanton

Powder Diffraction· Volume 36· Issue 2
Publisher page

Abstract

The crystal structure of tamsulosin hydrochloride has been solved and refined using synchrotron X-ray powder diffraction data and optimized using density functional techniques. Tamsulosin hydrochloride crystallizes in space group P 2 1 (#4) with a = 7.62988(2), b = 9.27652(2), c = 31.84996(12) Å, β = 93.2221(2)°, V = 2250.734(7) Å 3 , and Z = 4. In the crystal structure, two arene rings are connected by a carbon chain oriented roughly parallel to the c -axis. The crystal structure is characterized by two slabs of tamsulosin hydrochloride molecules perpendicular to the c -axis. As expected, each of the hydrogens on the protonated nitrogen atoms makes a strong hydrogen bond to one of the chloride anions. The result is to link the cations and anions into columns along the b -axis. One hydrogen atom of each sulfonamide group also makes a hydrogen bond to a chloride anion. The other hydrogen atom of each sulfonamide group forms bifurcated hydrogen bonds to two ether oxygen atoms. The powder pattern is included in the Powder Diffraction File™ as entry 00-065-1415.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: X-ray Diffraction in Crystallography · Crystallography and molecular interactions · Polymer Synthesis and Characterization

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (26)

Show source-provided references
1. 10.1017/S088571561800082910.1017/S0885715618000829 ↗
2. Crystallographic computing system JANA2006: general features10.1515/zkri-2014-1737 ↗
3. 10.1107/S002188981300353110.1107/S0021889813003531 ↗
4. Ham, Z. (2009). “Amorphous tamsulosin hydrochloride,” European Patent Specification EP 1713769 B1.
5. 10.1107/S090904950801843810.1107/S0909049508018438 ↗
6. 10.1017/S088571561400051710.1017/S0885715614000517 ↗
7. 10.1007/BF0054909610.1007/BF00549096 ↗
8. Gangakhedkar, K. K. (2006). “Polymorphic forms of (R)-(-)-tamsulosin,” International Patent Application WO 2006/117662 A2.
9. 10.1017/S088571561900081210.1017/S0885715619000812 ↗
10. 10.1063/1.296926010.1063/1.2969260 ↗
11. 10.1107/S205252061402290210.1107/S2052520614022902 ↗
12. 10.1107/S002188981301311310.1107/S0021889813013113 ↗
13. Wavefunction, Inc. (2018). Spartan ’18 Version 1.2.0, Wavefunction Inc., 18401 Von Karman Ave., Suite 370, Irvine, CA 92612.
14. 10.1002/jcc.2315310.1002/jcc.23153 ↗
15. Etudes sur la loi de bravais
16. 10.1107/S002188981101462210.1107/S0021889811014622 ↗
17. A new law of crystal morphology extending the law of bravais
18. 10.1002/qua.2465810.1002/qua.24658 ↗
19. 10.1016/j.molstruc.2014.03.04510.1016/j.molstruc.2014.03.045 ↗
20. 2019
21. 10.1063/1.46788210.1063/1.467882 ↗
22. Turner · 2017
23. 10.1107/S160057671901409210.1107/S1600576719014092 ↗
24. Bravais · 1866
25. 10.1107/S205252061600395410.1107/S2052520616003954 ↗
26. 10.1021/ci049780b10.1021/ci049780b ↗